Funding

Massachusetts-Based LifeMine Therapeutics Scores $263M in Funding

Aug 8, 2026 | By Devin Jacobs

SUMMARY

LifeMine Therapeutics raised $263 million.
It develops new medicines using AI and genomics.
The funding will support LIFE-001 and its pipeline.

LifeMine Therapeutics Inc., a Watertown, MA-based clinical-stage biopharmaceutical company leveraging digital genomics research technology, has raised $263 million in a funding round, bringing the total amount to $558 million.

The round included a $188 million Series E financing led by Milky Way Investments with participation from Bezos Expeditions, Gates Frontier, RA Capital Management, GV (Google Ventures), LoLa Capital Partners, GlaxoSmithKline (GSK), Invus, and ARCH Venture Partners, following a previously completed $75M Series D round.

The company will use the capital to accelerate clinical development of its lead drug candidate, LIFE-001, and advance its transplantation and immunology pipeline.

Funding Snapshot

Metric	Details
Latest Funding	$263 million
Series E	$188 million
Previous Series D	$75 million
Total Funding	$558 million
Lead Investor	Milky Way Investments
Company	LifeMine Therapeutics
Sector	Biotechnology, Biopharmaceuticals
Headquarters	Watertown, Massachusetts, US
Lead Program	LIFE-001

RECOMMENDED FOR YOU

Funding

[Funding News] AMI Raises Majority Investment from THL Partners

Team SR

Sep 10, 2024

Funding

HistoSonics Announces Financing with Participation from Yosemite

Devin Jacobs

Jun 23, 2026

Funding

Kincell Bio Raises $22 Mn Funding

Startuprise

May 17, 2025

About LifeMine Therapeutics

Founded in 2017 by Gregory Verdine, WeiQing Zhou, LifeMine Therapeutics is a clinical-stage biopharmaceutical company developing medicines through its Top-Down Drug Discovery™ platform.

The company's approach uses evolutionary insights from fungi alongside human genetics and genomics, bioinformatics, machine learning and synthetic biology to identify potential new medicines.

Core offerings include:

Precision medicine discovery
Transplantation therapies
Immunology drug development
Genomics-driven drug discovery
Machine learning-enabled research
Synthetic biology

Core Technologies / Products / Services

Technology/Product	Application/Use Case
Top-Down Drug Discovery™	Uses fungal evolutionary biology to identify therapeutic opportunities
Human Genomics	Identifies disease-related biological targets
Bioinformatics	Processes and interprets complex biological datasets
Machine Learning	Supports drug discovery and target identification
Synthetic Biology	Enables development and validation of therapeutic candidates
LIFE-001	Long-acting injectable candidate targeting calcineurin activation

Leadership Comments

"More than 1.6 million people worldwide are living with a transplanted organ, yet physicians continue to rely on calcineurin inhibitors that have remained largely unchanged for more than three decades despite their well-recognized toxicities,” said Gregory Verdine, Ph.D., Co-founder, President and Chief Executive Officer of LifeMine.

"Calcineurin inhibition remains the gold standard for preventing organ rejection, but today's therapies come with substantial toxicities that can compromise long-term patient outcomes because transplant recipients typically remain on these medicines for life," said Andrew Cameron, M.D., Surgeon-in-Chief of Johns Hopkins Hospital.